← CEO Central

J. David Joyner CEBS

CEO CEO, President & Chairman at CVS (CVS Health Corp.)

Summary

J. David Joyner is CVS Health's CEO, President and Chairman, having become CEO in October 2024 and Chairman in January 2026 after decades in health care and pharmacy benefit management.

Biography

Joyner began his career at Aetna as an employee benefit representative before joining Caremark Prescription Services in 1993. He held a range of sales, account management and pharmacy benefit management roles and later became an executive vice president overseeing sales and account services at CVS Caremark. After leaving CVS in 2020, Joyner returned in January 2023 as executive vice president and president of Pharmacy Services. He became President and CEO of CVS Health on October 17, 2024, succeeding Karen Lynch, and assumed the additional role of Chairman of the Board on January 1, 2026. Joyner holds a bachelor's degree in finance from Texas Tech University.

Notable achievements

  • Returned to CVS in 2023 to lead Pharmacy Services and CVS Caremark.
  • Reorganized senior leadership after becoming CEO, including changes across Aetna, Caremark, Pharmacy and Consumer Wellness, and Health Care Delivery.
  • Launched a company-wide turnaround effort focused on cost reduction, improved insurance margins and tighter capital discipline.
  • Oversaw CVS's decision to exit the Affordable Care Act individual exchange business in 2026 to reduce exposure to an underperforming market.
  • Led CVS during a 2025 year in which the company reported more than $402 billion in revenue and $14.4 billion in adjusted operating income.

Problem areas / controversies

  • He took over after severe pressure in Aetna, including elevated medical costs, weak Medicare Advantage profitability and repeated reductions to CVS's earnings outlook.
  • The turnaround has involved difficult actions, including reducing insurance-market participation and closing underperforming retail locations.
  • CVS continues to face questions about whether its insurance, pharmacy benefit management and retail businesses can produce consistent benefits from operating as one company.
  • No major personal regulatory or ethics controversy is prominent in the company's recent public filings, but his tenure remains closely associated with a turnaround that is still in progress.

Company